title: Imatinib therapy in chronic myelogenous leukemia and thyroid function tests.
abstract: BACKGROUND
  Imatinib, a tyrosine kinase inhibitor which resulted in much improvement in the treatment of chronic myelogenous leukemia (CML), may adversely affect thyroid gland function. To date, assessment of thyroid function during imatinib therapy has limited to retrospective studies. The aim of this study was to evaluate the effects of imatinib on thyroid function in a prospective manner.
  
  
  METHODS
  In this prospective study, 16 newly diagnosed adult subjects with positive Philadelphia chromosome in chronic phase of CML without any other apparent underlying diseases were enrolled. Free T3, Free T4, TSH, Anti TPO and Anti thyroglobulin antibodies were measured before and after 4 and 12 weeks of treatment.
  
  
  RESULTS
  Of the 16 patients, 9 were male (57.1%) and 7(42.9%) were female with a mean age of 29±5 years. There were statistically significant changes within reference ranges in serum concentrations of TSH (P=0.753 and 0.002), Free T3 (P=0.012 and 0.007) and Anti Thyroglobulin (P=0.221 and 0.041) 1 month before and 3 months after imatinib initiation, respectively. At the same time, there were no significant changes in serum Free T4 (P=0.196 and 0.650) and Anti TPO (P=0.807 and 0.600) concentrations.
  
  
  CONCLUSIONS
  This study showed some significant changes on thyroid function tests during imatinib therapy. However, all of them were within the normal range without any clinical abnormalities in the course of treatment. We recommend other studies with larger sample size and longer duration of follow-up.
authors: Health promotion research center, Zahedan University of Medical Sciences, Zahedan, Iran.
authors: Mohammad Ali
authors: MA
authors: Mashhadi
authors: Department of Internal medicine, Zahedan University of Medical Sciences, Zahedan, Iran.
authors: Mahmoud Ali
authors: MA
authors: Kaykhaei
authors: Health promotion research center, Zahedan University of Medical Sciences, Zahedan, Iran.
authors: Mahdi
authors: M
authors: Mohammadi
authors: Department of Internal medicine, Zahedan University of Medical Sciences, Zahedan, Iran.
authors: Mahdi
authors: M
authors: Hashemi
authors: Department of Internal medicine, Zahedan University of Medical Sciences, Zahedan, Iran.
authors: Tahere
authors: T
authors: Mohamadi Fatide
keywords: Chronic myelogenous leukemia; Imatinib mesylate; Thyroid function tests
references: N Engl J Med. 2006 May 11;354(19):2006-13
references: 16687713
references: Clin Pharmacol Ther. 2005 Oct;78(4):433-8
references: 16198662
references: Br J Cancer. 2008 Aug 5;99(3):448-54
references: 18665181
references: Thyroid. 2010 Nov;20(11):1209-14
references: 20929406
references: N Engl J Med. 2005 Jul 14;353(2):172-87
references: 16014887
references: Nat Med. 2006 Aug;12(8):908-16
references: 16862153
references: Ann Intern Med. 2006 Nov 7;145(9):660-4
references: 17088579
references: Eur J Endocrinol. 2008 May;158(5):771-2
references: 18426838
references: Nat Rev Clin Oncol. 2009 Apr;6(4):219-28
references: 19333228
references: Clin Lymphoma Myeloma. 2007 Mar;7 Suppl 3:S105-12
references: 17382019
references: J Clin Oncol. 2007 Jun 10;25(17):2369-76
references: 17557949
references: J Natl Cancer Inst. 2007 Jan 3;99(1):81-3
references: 17202116
references: Cancer. 2002 Aug 15;95(4):881-7
references: 12209733
references: N Engl J Med. 2006 Dec 7;355(23):2408-17
references: 17151364
references: N Engl J Med. 2008 Jul 3;359(1):31-42
references: 18596272